Shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shot up 9.3% on Thursday . The company traded as high as $0.70 and last traded at $0.6815. 1,486 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 1,855 shares. The stock had previously closed at $0.6236.
Avenue Therapeutics Trading Up 2.7%
The stock has a market capitalization of $2.31 million, a price-to-earnings ratio of 0.04 and a beta of -0.51. The stock’s 50 day moving average is $0.72 and its 200 day moving average is $0.65.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
See Also
- Five stocks we like better than Avenue Therapeutics
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
